New ALS Drug Approved in Canada While Still Under FDA Review
MONDAY, June 13, 2022 (HealthDay News) — An experimental drug for the neurological disorder ALS was approved in Canada on Monday, but an ongoing evaluation of the treatment by the U.S. Food and Drug Administration has raised questions about its effectiveness. A condition of Health Canada’s approval of Albrioza (AMX0035)Continue Reading